Skip to content

Abbott ABT EPS (Diluted)

EPS (Diluted) at other companies

Becton, Dickinson and Company logo
Becton, Dickinson and CompanyBDX
-$1.11-204%
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
-$19.55-954%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$2.14-52.9%
Haemonetics logo
HaemoneticsHAE
$0.95+28.4%
Merit Medical Systems logo
Merit Medical SystemsMMSI
$0.68+38.8%
Boston Scientific logo
Boston ScientificBSX
$0.90+100%

Other financials

Income statement

See full
Revenue$11.2B+7.8%
Gross profit$6.3B+6.5%
Operating income$1.3B-20.6%
Net income$1.1B-18.7%

Balance sheet

See full
Cash & equivalents$6.8B+4.1%
Total debt$34.0B+157%
Total equity$52.1B+6.7%
Total assets$110.43B+35.6%

Cash flow

See full
Operating cash flow$1.3B-7.2%
CapEx$399.0M-17.6%
Free cash flow$916.0M-1.8%

Valuation

See full
Market cap$162.41B-29.8%
Enterprise value$189.65B-20.3%
P/E25.9×+8.7×
P/S3.6×-1.9×

Profitability

See full
Gross margin56.3%+0.4pp
Operating margin17.1%+0.2pp
Net margin13.9%-18.0pp
FCF margin16.3%+0.6pp

Returns & leverage

See full
Return on equity12.4%-18.4pp
Debt / equity0.7×+0.4×
Current ratio1.4×-0.4×

Where this comes from

Reported directly by Abbott in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The official record: Abbott’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Abbott's eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Abbott's EPS (diluted)?
Abbott (ABT) reported EPS (diluted) of $0.61 in Q1 2026.
How has Abbott's EPS (diluted) changed year-over-year?
Abbott's EPS (diluted) decreased by 19.7% year-over-year, from $0.76 to $0.61.
What is the long-term trend for Abbott's EPS (diluted)?
Over 4 years (2021 to 2025), Abbott's EPS (diluted) has grown at a -1.4% compound annual growth rate (CAGR), from $3.94 to $3.73.
What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.